Free
Correspondence  |   June 2014
Psychedelics, Glutamate, and Neuroimaging Studies
Author Affiliations & Notes
  • Rafael G. dos Santos, Ph.D.
    Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil, and International Center for Ethnobotanical Education, Research and Service, Halsteren, The Netherlands. banisteria@gmail.com
  • (Accepted for publication March 5, 2014.)
    (Accepted for publication March 5, 2014.)×
Article Information
Correspondence
Correspondence   |   June 2014
Psychedelics, Glutamate, and Neuroimaging Studies
Anesthesiology 06 2014, Vol.120, 1521-1522. doi:10.1097/ALN.0000000000000243
Anesthesiology 06 2014, Vol.120, 1521-1522. doi:10.1097/ALN.0000000000000243
To the Editor:
The article by Icaza and Mashour1  is a very interesting article because it presents a topic of investigation that is currently attracting the attention of pharmacologists, neuroscientists, and biological psychiatrists around the globe: human research with psychedelic compounds. The text brings important information regarding the history and pharmacology of psychedelics but presents important limitations that are discussed below.
In the first place, by focusing the neurochemistry discussion on N-methyl-d-aspartate antagonism and γ-aminobutyric acidergic activity in interneurons, the text narrows its focus and presents limited information regarding the importance of glutamate in the neurochemistry of the effects produced by psychedelic drugs. The head-twitch behavioral response, a mouse behavioral proxy of human psychedelic action, is induced by all psychedelic 5-HT2A receptor agonists, and this behavior is decreased in knockout mice for the metabotropic glutamate 2 (mGlu2) receptor.2,3  Moreover, this receptor has been shown to be expressed in close molecular proximity with the 5-HT2A receptor in tissue culture and mouse frontal cortex.3,4 
Second, Icaza and Mashour1  affirm that “Only one psychedelic drug—psilocybin—was discussed because this is the only classic psychedelic drug that has been studied with neuroimaging in humans.” This statement is not in line with the literature on psychedelic drugs, which is rich in neuroimaging human studies not only after administration of psilocybin5  but also after administration of the classic psychedelics mescaline,6  dimethyltryptamine,7,8  and the dimethyltryptamine-rich botanical preparation ayahuasca.9–12 
Finally, the literature on neuroimaging studies and psilocybin is not fully discussed and integrated in the article by Icaza and Mashour. There are important and contrasting data among the studies published to date, and these studies have not been included or discussed. How the decreases in cerebral blood flow and blood oxygen level–dependent signal detected after the intravenous administration of psilocybin in a functional magnetic resonance imaging study13  can be interpreted in light of the global increases in the cerebral metabolic rate of glucose after oral psilocybin administration in earlier positron emission tomography studies?14,15  Is there any pharmacokinetic or pharmacodynamic difference between intravenous and oral psilocybin administration, which could modify the brain’s rate of psilocin uptake, changing the neuroimaging patterns observed? These are the types of fundamental questions for future research.
Competing Interests
The author declares no competing interests.
Rafael G. dos Santos, Ph.D., Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil, and International Center for Ethnobotanical Education, Research and Service, Halsteren, The Netherlands. banisteria@gmail.com
References
Icaza, EE, Mashour, GA Altered states: Psychedelics and anesthetics.. Anesthesiology. (2013). 119 1255–60 [Article] [PubMed]
Moreno, JL, Holloway, T, Albizu, L, Sealfon, SC, González-Maeso, J Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists.. Neurosci Lett. (2011). 493 76–9 [Article] [PubMed]
Hanks, JB, González-Maeso, J Animal models of serotonergic psychedelics.. ACS Chem Neurosci. (2013). 4 33–42 [Article] [PubMed]
González-Maeso, J, Ang, RL, Yuen, T, Chan, P, Weisstaub, NV, López-Giménez, JF, Zhou, M, Okawa, Y, Callado, LF, Milligan, G, Gingrich, JA, Filizola, M, Meana, JJ, Sealfon, SC Identification of a serotonin/glutamate receptor complex implicated in psychosis.. Nature. (2008). 452 93–7 [Article] [PubMed]
Studerus, E, Kometer, M, Hasler, F, Vollenweider, FX Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies.. J Psychopharmacol. (2011). 25 1434–52 [Article] [PubMed]
Hermle, L, Fünfgeld, M, Oepen, G, Botsch, H, Borchardt, D, Gouzoulis, E, Fehrenbach, RA, Spitzer, M Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research.. Biol Psychiatry. (1992). 32 976–91 [Article] [PubMed]
Daumann, J, Heekeren, K, Neukirch, A, Thiel, CM, Möller-Hartmann, W, Gouzoulis-Mayfrank, E Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis.. Psychopharmacology (Berl). (2008). 200 573–83 [Article] [PubMed]
Daumann, J, Wagner, D, Heekeren, K, Neukirch, A, Thiel, CM, Gouzoulis-Mayfrank, E Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis.. J Psychopharmacol. (2010). 24 1515–24 [Article] [PubMed]
Riba, J, Romero, S, Grasa, E, Mena, E, Carrió, I, Barbanoj, MJ Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant.. Psychopharmacology (Berl). (2006). 186 93–8 [Article] [PubMed]
Dos Santos, RG, Valle, M, Bouso, JC, Nomdedéu, JF, Rodríguez-Espinosa, J, McIlhenny, EH, Barker, SA, Barbanoj, MJ, Riba, J Autonomic, neuroendocrine, and immunological effects of ayahuasca: A comparative study with. d. -amphetamine.. J Clin Psychopharmacol. (2011). 31 717–26 [Article] [PubMed]
Dos Santos, RG, Grasa, E, Valle, M, Ballester, MR, Bouso, JC, Nomdedéu, JF, Homs, R, Barbanoj, MJ, Riba, J Pharmacology of ayahuasca administered in two repeated doses.. Psychopharmacology (Berl). (2012). 219 1039–53 [Article] [PubMed]
de Araujo, DB, Ribeiro, S, Cecchi, GA, Carvalho, FM, Sanchez, TA, Pinto, JP, de Martinis, BS, Crippa, JA, Hallak, JE, Santos, AC Seeing with the eyes shut: Neural basis of enhanced imagery following Ayahuasca ingestion.. Hum Brain Mapp. (2012). 33 2550–60 [Article] [PubMed]
Carhart-Harris, RL, Erritzoe, D, Williams, T, Stone, JM, Reed, LJ, Colasanti, A, Tyacke, RJ, Leech, R, Malizia, AL, Murphy, K, Hobden, P, Evans, J, Feilding, A, Wise, RG, Nutt, DJ Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.. Proc Natl Acad Sci U S A. (2012). 109 2138–43 [Article] [PubMed]
Vollenweider, FX, Leenders, KL, Scharfetter, C, Maguire, P, Stadelmann, O, Angst, J Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.. Neuropsychopharmacology. (1997). 16 357–72 [Article] [PubMed]
Gouzoulis-Mayfrank, E, Schreckenberger, M, Sabri, O, Arning, C, Thelen, B, Spitzer, M, Kovar, KA, Hermle, L, Büll, U, Sass, H Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and. d. -methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG.. Neuropsychopharmacology. (1999). 20 565–81 [Article] [PubMed]